Addimag 240 mg/ml + 126 mg/ml solution for infusion for cattle
Addimag 240 mg/ml + 126 mg/ml solution for infusion for cattle
Authorised
- Calcium gluconate monohydrate
- Magnesium chloride hexahydrate
Product identification
Medicine name:
Addimag 240 mg/ml + 126 mg/ml Solution pour perfusion
Addimag 240 mg/ml + 126 mg/ml Oplossing voor infusie
Addimag 240 mg/ml + 126 mg/ml Infusionslösung
Addimag 240 mg/ml + 126 mg/ml solution for infusion for cattle
Active substance:
- Calcium gluconate monohydrate
- Magnesium chloride hexahydrate
Target species:
-
Cattle
Route of administration:
-
Solution for infusion
Product details
Active substance and strength:
-
Calcium gluconate monohydrate240.00milligram(s)1.00millilitre(s)
-
Magnesium chloride hexahydrate126.00milligram(s)1.00millilitre(s)
Pharmaceutical form:
-
Concentrate for solution for infusion
Withdrawal period by route of administration:
-
Solution for infusion
- Cattle
-
Meat and offalno withdrawal period
-
Milkno withdrawal period
-
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QA12AX
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
This information is not available for this product.
Package description:
- 750 ml square shaped clear polypropylene (PP) bottle with a bromobutyl rubber stopper and an aluminium screw cap.
- 500 ml square shaped clear polypropylene (PP) bottle with a bromobutyl rubber stopper and an aluminium screw cap
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Alfasan Nederland B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
- Alfasan Nederland B.V.
- Bela-Pharm GmbH & Co. KG
Responsible authority:
- Federal Agency For Medicines And Health Products
Authorisation number:
- BE-V660952
Date of authorisation status change:
Reference member state:
-
Netherlands
Procedure number:
- NL/V/0352/002/DC
Concerned member states:
-
Austria
-
Belgium
-
Bulgaria
-
Croatia
-
Cyprus
-
Czechia
-
Denmark
-
Estonia
-
Finland
-
France
-
Germany
-
Greece
-
Hungary
-
Iceland
-
Ireland
-
Italy
-
Latvia
-
Lithuania
-
Luxembourg
-
Norway
-
Poland
-
Portugal
-
Romania
-
Slovakia
-
Slovenia
-
Spain
-
Sweden
-
United Kingdom (Northern Ireland)
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Summary of Product Characteristics
This document does not exist in this language (English). You can find it in another language below.
Package Leaflet
This document does not exist in this language (English). You can find it in another language below.
Combined File of all Documents
English (PDF)
Download Published on: 25/04/2022
How useful was this page?: